FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054381014> ?p ?o ?g. }

• W2054381014 endingPage "319" @default.
• W2054381014 startingPage "318" @default.
• W2054381014 abstract "Pioglitazone, a member of the thiazolidinedione (TZD) drug family, is widely used for the treatment of Type 2 diabetic patients. This antihyperglycaemic drug is a selective ligand of the nuclear transcription factor, peroxisome proliferator-activated receptor (PPAR) γ. It interacts with PPARγ receptors that are located predominantly in adipose, hepatic and skeletal muscle cells. Modulation of these receptors adjusts the regulation of genes involved in metabolic control and also reduces insulin resistance [1]. However, pioglitazone is known to induce body weight gain [2–4]. Therefore, it is important to control the body weight in usage of PPAR ligands in the treatment of Type 2 diabetes. Alpha glycosidase inhibitors (AGIs) such as voglibose are known to inhibit disaccharide hydrolysis in intestinal mucosa, thereby reducing the hydrolysis of disaccharides to monosaccharides. This impedes absorption of carbohydrate and therefore reduces glucose levels in Type 2 diabetes patients. We have investigated whether it is possible to prevent pioglitazone-induced body weight gain with voglibose treatment. A total of 31 randomly chosen Japanese Type 2 diabetic patients (14 men, 17 women) was recruited into this study. One group was treated for >3 months with diet alone (control group; n = 17, age 60.2 ± 2.5 years, duration of diabetes 11.7 ± 1.5 years); the other was treated with diet plus voglibose (0.9 mg daily) (voglibose group; n = 14, age 61.1 ± 3.6 years, duration of diabetes 9.6 ± 1.3 years). Pioglitazone treatment was given to each group at the dose of 15 mg for 3 months, and dosage was increased to 30 mg for the next 9 months. Diet therapy consisted of 104.6 kJ kg–1 of ideal body weight per day. All patients were instructed to maintain the same energy intake and physical activity as usual for the individual. There was no significant difference in HbA1c levels (8.1 ± 0.3% for control group, 7.9 ± 0.3 for voglibose group) or body mass index (25.9 ± 1.5 for control group, 26.3 ± 1.2 for voglibose group) prior to the trial. Body weight was examined at the beginning and the end of the study. Four patients (one male and three female) dropped out of the trial due to the side-effects of pioglitazone (oedema). There was no significant difference in body weight between the control and voglibose groups before starting the pioglitazone (68.1 ± 5.0 kg for the control group, 72.7 ± 4.7 kg for the voglibose group: the body weight of the voglibose group prior to voglibose treatment was 72.6 ± 4.5 kg). Body weight increased by 0.1 ± 0.3 kg (0.02%) in the voglibose group and 2.5 ± 0.4 kg (3.7%) in the control group (P < 0.01) after pioglitazone treatment (Fig. 1). This result suggests that voglibose treatment prevents the body weight gain induced by pioglitazone. The effect of pioglitazone on body weight change with and without voglibose. *P < 0.01. Student's t-test was used for baseline comparison Clinically, it has been shown that TZDs specifically increase subcutaneous adipose tissue [5]. Body weight gain was significantly greater within 4 weeks; it increased on average by 3.88 kg (4.1%) and it did not reach a plateau even after 6 months [5, 6]. In our study, the body weight gain of 3.7% in the pioglitazone monotherapy control group was consistent with these clinical studies. Voglibose is reported to cause side-effects on the small intestine, such as abdominal fullness or diarrhoea for the first several months. These side-effects usually disappear by intestinal adaptation within a couple of months. Since patients require several months to adapt to voglibose, it may be important to start voglibose therapy several months prior to pioglitazone therapy to achieve prevention of body weight gain by pioglitazone. The precise mechanism whereby voglibose may prevent pioglitazone-induced body weight gain is unclear. AGIs have been reported to have no effects on body weight gain or intestinal mass when applied alone [7]. Indeed, in a separate study, we found that monotherapy of voglibose failed to reduce body weight in Type 2 diabetic patients (data not shown). There has been a report that body weight significantly decreased by the combination therapy of acarbose and sulphonylurea compared with sulphonylurea alone [8]. The subjects included in this study did not experience loss of appetite. Therefore, it is likely that the observed effects were independent of the appetite control or intestinal factors. AGIs are known to reduce insulin levels, and it is therefore likely that insulin level of subjects included in this study were reduced [9, 10]. Hyperinsulinaemia can cause body weight gain. We hypothesize that voglibose treatment prior to pioglitazone may have reduced the serum insulin levels, and thus pioglitazone was applied after the reduced insulin levels were established. Therefore, pioglitazone may have improved insulin resistance through this lack of increase in body weight of the patients. To confirm this hypothesis, further investigations are required. In conclusion, we have found that voglibose treatment prevented the increase of body weight induced by pioglitazone in Type 2 diabetes patients. Thus, voglibose may be a potentially useful drug for increasing the benefit of pioglitazone treatment by controlling body weight. Competing interest: None declared." @default.
• W2054381014 created "2016-06-24" @default.
• W2054381014 creator A5035127351 @default.
• W2054381014 creator A5036207046 @default.
• W2054381014 creator A5042878583 @default.
• W2054381014 creator A5091072100 @default.
• W2054381014 creator A5091627597 @default.
• W2054381014 date "2008-07-14" @default.
• W2054381014 modified "2023-10-18" @default.
• W2054381014 title "Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients" @default.
• W2054381014 cites W1987692887 @default.
• W2054381014 cites W1999236387 @default.
• W2054381014 cites W2031773477 @default.
• W2054381014 cites W2041850770 @default.
• W2054381014 cites W2049075991 @default.
• W2054381014 cites W2096666904 @default.
• W2054381014 cites W2107207934 @default.
• W2054381014 cites W2136324712 @default.
• W2054381014 cites W4245059944 @default.
• W2054381014 doi "https://doi.org/10.1111/j.1365-2125.2008.03216.x" @default.
• W2054381014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2492932" @default.
• W2054381014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18507653" @default.
• W2054381014 hasPublicationYear "2008" @default.
• W2054381014 type Work @default.
• W2054381014 sameAs 2054381014 @default.
• W2054381014 citedByCount "21" @default.
• W2054381014 countsByYear W20543810142013 @default.
• W2054381014 countsByYear W20543810142014 @default.
• W2054381014 countsByYear W20543810142015 @default.
• W2054381014 countsByYear W20543810142016 @default.
• W2054381014 countsByYear W20543810142017 @default.
• W2054381014 countsByYear W20543810142019 @default.
• W2054381014 countsByYear W20543810142020 @default.
• W2054381014 countsByYear W20543810142021 @default.
• W2054381014 countsByYear W20543810142022 @default.
• W2054381014 crossrefType "journal-article" @default.
• W2054381014 hasAuthorship W2054381014A5035127351 @default.
• W2054381014 hasAuthorship W2054381014A5036207046 @default.
• W2054381014 hasAuthorship W2054381014A5042878583 @default.
• W2054381014 hasAuthorship W2054381014A5091072100 @default.
• W2054381014 hasAuthorship W2054381014A5091627597 @default.
• W2054381014 hasBestOaLocation W20543810142 @default.
• W2054381014 hasConcept C126322002 @default.
• W2054381014 hasConcept C134018914 @default.
• W2054381014 hasConcept C170493617 @default.
• W2054381014 hasConcept C171089720 @default.
• W2054381014 hasConcept C187345961 @default.
• W2054381014 hasConcept C2776923340 @default.
• W2054381014 hasConcept C2777180221 @default.
• W2054381014 hasConcept C2777391703 @default.
• W2054381014 hasConcept C2778384471 @default.
• W2054381014 hasConcept C555293320 @default.
• W2054381014 hasConcept C71924100 @default.
• W2054381014 hasConcept C98274493 @default.
• W2054381014 hasConceptScore W2054381014C126322002 @default.
• W2054381014 hasConceptScore W2054381014C134018914 @default.
• W2054381014 hasConceptScore W2054381014C170493617 @default.
• W2054381014 hasConceptScore W2054381014C171089720 @default.
• W2054381014 hasConceptScore W2054381014C187345961 @default.
• W2054381014 hasConceptScore W2054381014C2776923340 @default.
• W2054381014 hasConceptScore W2054381014C2777180221 @default.
• W2054381014 hasConceptScore W2054381014C2777391703 @default.
• W2054381014 hasConceptScore W2054381014C2778384471 @default.
• W2054381014 hasConceptScore W2054381014C555293320 @default.
• W2054381014 hasConceptScore W2054381014C71924100 @default.
• W2054381014 hasConceptScore W2054381014C98274493 @default.
• W2054381014 hasIssue "2" @default.
• W2054381014 hasLocation W20543810141 @default.
• W2054381014 hasLocation W20543810142 @default.
• W2054381014 hasLocation W20543810143 @default.
• W2054381014 hasLocation W20543810144 @default.
• W2054381014 hasOpenAccess W2054381014 @default.
• W2054381014 hasPrimaryLocation W20543810141 @default.
• W2054381014 hasRelatedWork W1964594176 @default.
• W2054381014 hasRelatedWork W1997608114 @default.
• W2054381014 hasRelatedWork W2012211007 @default.
• W2054381014 hasRelatedWork W2034262940 @default.
• W2054381014 hasRelatedWork W2046213534 @default.
• W2054381014 hasRelatedWork W2423365100 @default.
• W2054381014 hasRelatedWork W2509842036 @default.
• W2054381014 hasRelatedWork W2951098600 @default.
• W2054381014 hasRelatedWork W2981604045 @default.
• W2054381014 hasRelatedWork W3193406464 @default.
• W2054381014 hasVolume "66" @default.
• W2054381014 isParatext "false" @default.
• W2054381014 isRetracted "false" @default.
• W2054381014 magId "2054381014" @default.
• W2054381014 workType "article" @default.